Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention

Slides:

Advertisements

Similar presentations

Sex- and Gender-Related Risk Factor Burden in Patients With Premature Acute Coronary Syndrome Jin Choi, MSc, Stella Styliani Daskalopoulou, MD, MSc, PhD,

Advertisements

Diabetes Management in Long-Term Care: An Exploratory Study of the Current Practices and Processes to Managing Frail Elderly Persons with Type 2 Diabetes.

The “no reflow” phenomenon following acute myocardial infarction: Mechanisms and treatment options Sanjiv Kaul, MD Journal of Cardiology Volume 64, Issue.

Radiofrequency catheter ablation of incessant atrial tachycardia in pregnant women with minimal radiation exposure: Lessons from two case studies Pil-Sung.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Volume 370, Issue 9586, Pages (August 2007)

To Anticoagulate or not to Anticoagulate

Kiran Sidhu, MD, FRCPC, Anthony Tang, MD, FRCPC

Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients—Analysis of Pharmaceuticals and Medical Devices Agency Data

Aligning Health Care Policy With Evidence-Based Medicine: The Case for Funding Direct Oral Anticoagulants in Atrial Fibrillation James A. Stone, MD,

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

American Heart Journal

171 The risk stratification and stroke prevention therapy care gap in canadian atrial fibrillation patients: Insights from the Facilitating Review and.

A Novel Approach to Cardiovascular Health By Optimizing Risk Management (ANCHOR): Behavioural Modification in Primary Care Effectively Reduces Global.

A Novel Approach to Cardiovascular Health By Optimizing Risk Management (ANCHOR): Behavioural Modification in Primary Care Effectively Reduces Global.

Frontiers of anticoagulation therapy for atrial fibrillation

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence David D. Waters, MD, Sripal Bangalore, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

The Demise of Morphine Oxygen Nitroglycerin Aspirin (MONA)

The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines Laurent Macle, MD,

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD, John Cairns, MD, Kori.

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation Lena Rivard, MD, MSc, Paul Khairy, MD,

Volume 137, Issue 2, Pages (February 2010)

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Sandra Lauck, RN, PhD, Dion Stub, MD, PhD, John Webb, MD

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Trend in Mortality after Stroke with Atrial Fibrillation

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters,

The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines Laurent Macle, MD,

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

Health Care Use and Associated Time and Out of Pocket Expenditures for Patients With Cardiovascular Disease in a Publicly Funded Health Care System Saba.

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Atul Verma, MD, John A. Cairns, MD, L.

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review Truman.

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes Amer M.

2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Jason G. Andrade, MD, Atul Verma, MD,

Amy C. Arnold, PhD, MSCI, Satish R. Raj, MD, MSCI

Atrial fibrillation: Improvement in identification and stroke preventive therapy —Data from the UK Clinical Practice Research Datalink, 2000–2012 A.C.E.

Patient Preferences in Treatment Choices for Early-Stage Lung Cancer

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Patient attitudes toward issues of environmental health

Whatever Will Be, Will Be: Spontaneous Chest Wall Hematoma With Regular Use of Low-Dose Acetylsalicylic Acid Rasih Yazkan, MD, Kadir Ceviker, MD, Hasan.

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Catheter Ablation for Atrial Fibrillation/Atrial Flutter Atul Verma, MD, FRCPC,

Simon M. Glynn, MD, Sean J. Pittock, MD, Steven A. Vernino, MD, PhD

National Trends in Ambulatory Oral Anticoagulant Use

Andrew D. Krahn, MD, Shubhayan Sanatani, MD, Martin J

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation Mihoko Kawabata,

Erratum Canadian Journal of Cardiology

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management Anne M. Gillis, MD, FRCPC, Atul Verma, MD, FRCPC, Mario.

SAFETY AND EFFICACY OF DABIGATRAN COMPARED TO BRIDGED WARFARIN FOR PERIPROCEDURAL ANTICOAGULATION IN PATIENTS UNDERGOING RADIOFREQUENCY ABLATION FOR.

Although non-stroke outcomes are more common, stroke risk scores can be used for prediction in patients with atrial fibrillation Finlay A. McAlister,

Fig. 2. Quarterly trend of OAC prescription among patients with atrial fibrillation from HIRA-NPS between 2013 and Solid line = results of segmented.

P. Timothy Pollak, MD, PhD, FRCPC, L. Brent Mitchell, MD, FRCPC

Mobile Medicine: Digital Dynamo or Virtual Vaporware

Targeted Therapeutic Drug Monitoring for Direct Oral Anticoagulants: What Is Its Potential Place and Can It Limit Black Swan Events? D. George Wyse,

Management of Atrial Fibrillation by Canadian Electrophysiologists After Early Termination of the PALLAS Study Kiarash Mohajer, BSc, Ben Fregeau, BSc,

Presentation transcript:

Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention Jason G. Andrade, MD, Andrew D. Krahn, MD, Allan C. Skanes, MD, Daniel Purdham, PhD, Antonio Ciaccia, MSc, Sean Connors, MD, PhD Canadian Journal of Cardiology Volume 32, Issue 6, Pages 747-753 (June 2016) DOI: 10.1016/j.cjca.2015.09.023 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Results of the physician survey regarding oral anticoagulant preferences and practices. (A) The physician stated preferred anticoagulant profile (on the basis of attribute profile alone, with no knowledge of the specific agent; note: attributes of dabigatran were not included). (B) The physician stated spontaneously volunteered preferred anticoagulant agent. (C) The relative proportion of agents prescribed among the past 10 patients. Canadian Journal of Cardiology 2016 32, 747-753DOI: (10.1016/j.cjca.2015.09.023) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Conjoint analysis. The relative importance of each attribute (ie, the measure of how much effect an attribute has relative to the other attributes), independently assessed by patients and physicians. Canadian Journal of Cardiology 2016 32, 747-753DOI: (10.1016/j.cjca.2015.09.023) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Perception regarding the degree of collaboration for oral anticoagulant initiation. Among patients who were presented with several treatment options by their physician the perception regarding the individual making the ultimate treatment decision differed among patients and physicians. Canadian Journal of Cardiology 2016 32, 747-753DOI: (10.1016/j.cjca.2015.09.023) Copyright © 2016 The Authors Terms and Conditions

Figure 4 Therapy adherence. (A) Proportion of patients with missed doses of their anticoagulant in the past week, stratified according to agent and number of missed doses. (B) Proportion of patients who are currently using the wrong dosing frequency of their anticoagulant. (C) Proportion of patients who had considered stopping their anticoagulant therapy within the past year. OAC, oral anticoagulant. Canadian Journal of Cardiology 2016 32, 747-753DOI: (10.1016/j.cjca.2015.09.023) Copyright © 2016 The Authors Terms and Conditions